Indiana Health Insurance
Talk with an Expert:1-877-210-2010

Insurance in Indianapolis Indiana and Alzheimer’s

Insurance in Indianapolis Indiana, available through CRinsure.com, has learned that there may have been a major breakthrough in the treatment of Alzheimer’s disease. The Case Western Reserve University School of Medicine’s neuroscientists have been conducting studies that, as reported in the journal Science, reveal that a drug is proving positive in the treatment of mice in renewing deficits in cognitive functions, memory functions, and pathological functions.

The new drug, according to studies made available to insurance in Indianapolis Indiana, is called bexarotene. Bexarotene is already on the market in the U.S. The FDA approved it over a decade ago for the treatment of cancer.

As the human brain functions, it creates amyloid beta, which must be cleared from the cells of the brain. The healthy brain does this with no problem. The brain has a cholesterol carrier called ApoE that clears out the amyloid beta cells. However, in patients with Alzheimers, the ApoE production is inhibited or stopped, allowing the amyloid beta cells to build up in the brain impairing functions. Dr. Gary Landreth, professor of neurosciences at Case Western, began testing with bexarotene to see if it would trigger the formation of ApoE in the brain. If it would do so, it would mean that the damaging amyloid betas would be removed from affected brains at a rate that existed before the malfunction.

Insurance in Indianapolis Indiana discovered that the research conducted by Dr. Landreth and his team proved that the bexarotene triggered the formation of retinoid X receptors that regulate ApoE formation. In fact, the speed at which the bexarotene improved the memories and behaviors in the test mice, and even the effect on the pathology of the disease itself, was astonishing. In the studies with animals and humans as well, it was observed that even small amounts of amyloid beta created significant memory problems. However, the amyloid beta levels decreased by 25% just 6 hours after the administration of bexarotene. Not only did the amyloid beta levels go down significantly, but in the mice, it was observed that there was a rapid and significant improvement in many of the behaviors associated with Alzheimer’s.

For example, in the tests on mice, researchers observed that mice with Alzheimer’s didn’t know what to do with nesting materials provided to them. Whereas healthy mice would automatically begin to make nests with the materials, the affected mice did not. However, a mere 72 hours after the administration of bexarotene, those same mice regained their instinct to nest, and knew what to do with the materials provided. The drug also improved the mice’s abilities to smell and respond to scents. The sense of smell is one of the first indicators of Alzheimer’s. The bexarotene also significantly reduced amyloid plaques that build up in the brain – again within 72 hours. The plaques were reduced by 75%.

Insurance in Indianapolis Indiana is excited to see further studies conducted in this area. As soon as the testing phase is complete, the FDA should be set to approve bexarotene for the treatment of Alzheimer’s.

For a free, instant quote you can contact an agent at 1-877-210-2010 or contact us via our company’s website.